QualiMedLab Srl, Scuola Superiore Sant'Anna, Fondazione CNR-Regione Toscana G. Monasterio, Istituto di Fisiologia Clinica del CNR, Pisa, Italy.
Clin Chem Lab Med. 2011 Oct;49(10):1669-76. doi: 10.1515/CCLM.2011.647. Epub 2011 Jun 17.
In order to evaluate whether there is still present a very large variability in measured values and analytical performance among different free thyroid (FT) hormone immunoassays, we considered the results derived from an External Quality Assessment (EQA) scheme, named Immunocheck.
The EQA Immonocheck study enrolled about 1000 participant laboratories, which measured the 54 quality control samples distributed in the three annual cycles (2007, 2008 and 2009). Participant laboratories produced a total of 30,476 results for FT3 and 31,351 for FT4, respectively.
The results recovered during the EQA cycles allowed the estimation of assay imprecision (i.e., within-method and between-laboratories variability). On average, control samples with lower free triiodothyronine (FT3) and free thyroxine (FT4) concentrations showed higher imprecision values (CV%) than those with levels within or above the normal range. The agreement among the results produced by different methods was estimated by computing the percent differences (i.e., percent bias values) between the concentrations measured by the methods and the mean of all collected results (i.e., consensus mean).
The results of our study demonstrate that a large variability in measured values is still present among different free thyroid hormone immunoassays. Indeed, some immunoassays for both FT3 and FT4 measurement showed percent bias values compared to the consensus mean >20%. Laboratories should inform the clinicians about analytical performance and reference limits of the method used. Furthermore, the clinicians should avoid the use of different methods in the follow-up of patients.
为了评估不同游离甲状腺(FT)激素免疫分析之间测量值和分析性能是否仍存在很大差异,我们考虑了外部质量评估(EQA)方案 Immunocheck 的结果。
EQA Immunocheck 研究共纳入约 1000 个参加实验室,这些实验室在三个年度周期(2007 年、2008 年和 2009 年)中测量了分布的 54 个质量控制样本。参加实验室分别为 FT3 产生了 30476 个结果,为 FT4 产生了 31351 个结果。
EQA 周期中回收的结果允许估计分析不精密度(即,方法内和实验室间变异性)。平均而言,游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)浓度较低的对照样本显示出更高的不精密度值(CV%),而浓度在正常范围内或以上的对照样本则较低。通过计算方法测量的浓度与所有收集结果的平均值(即共识平均值)之间的差异百分比(即偏倚值百分比),来估计不同方法之间的结果一致性。
我们的研究结果表明,不同游离甲状腺激素免疫分析之间的测量值仍存在很大差异。事实上,一些用于测量 FT3 和 FT4 的免疫分析与共识平均值相比,偏倚值百分比>20%。实验室应向临床医生告知所用方法的分析性能和参考限值。此外,临床医生应避免在患者随访中使用不同的方法。